Archivum Immunologiae et Therapiae Experimentalis

Papers
(The TQCC of Archivum Immunologiae et Therapiae Experimentalis is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study43
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model34
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer34
Antioxidant and Anti-inflammatory Effects of α-Lipoic Acid on Lipopolysaccharide-induced Oxidative Stress in Rat Kidney30
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity29
Immunology and Donor-Specific Antibodies in Corneal Transplantation29
Correction to: In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy21
Should Nano-Particles be Weighed or Counted? Technical Considerations to In Vitro Testing Originated from Corpuscular Nature of Nano-Particles21
Sex Differences in Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer’s Disease Patients20
Mast Cells and Resistance to Immunotherapy in Cancer17
What Has Immunology Brought to Periodontal Disease in Recent Years?17
Small Extracellular Vesicles Loaded with Immunosuppressive miRNAs Leads to an Inhibition of Dendritic Cell Maturation17
Peroxiredoxins as Markers of Oxidative Stress in IgA Nephropathy, Membranous Nephropathy and Lupus Nephritis17
Chronic Prostatitis and Pelvic Pain Syndrome: Another Autoimmune Disease?16
Elevated Levels of Soluble CD147 are Associated with Hyperinflammation and Disease Severity in COVID-19: A Proof-of-Concept Clinical Study14
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic–Intraosseous Administration13
Molecular Genetics Diversity of Primary Hemophagocytic Lymphohistiocytosis among Polish Pediatric Patients11
0.02890682220459